Latest News for: parkinson's disease

Edit

New daily pill improves Parkinson's symptoms in phase 3 trial (Parkinson's Disease Society of the United Kingdom)

Public Technologies 08 Oct 2026
Parkinson's Disease Society of the United Kingdom published this content on October 08, 2026, and is solely responsible for the information contained herein.
Edit

Daily pill for Parkinson's disease raises hopes patients could see first major new class of ...

The Daily Mail 08 Oct 2026
The drug significantly reduced the amount of time patients spent struggling with the stiffness, slowness and tremors associated with the condition ....
Edit

Parkinson's UK funded drug improves movement symptoms in early trial (Parkinson's Disease Society of the United Kingdom)

Public Technologies 07 Oct 2026
Parkinson's Disease Society of the United Kingdom published this content on October 07, 2026, and is solely responsible for the information contained herein.
Edit

Mentara Therapeutics Launches to Advance MTA-304, a Phase 2-Ready PDE10A Inhibitor, for Levodopa-Induced Dyskinesia in Parkinson's Disease

PR Newswire 07 Oct 2026
Levodopa is still the most effective treatment for Parkinson's disease ... "People with Parkinson's shouldn't have to trade symptom control for dyskinesia," said Frank Stonebanks, CEO of Mentara Therapeutics.
Edit

KDventures portfolio company Umecrine Cognition invited to showcase Parkinson's disease program and new translational data at The Michael J. Fox Foundation's PDTC 2026 (KDventures AB)

Public Technologies 07 Oct 2026
2026-10-07 13.00.00 CEST KDventures AB - Investor News KDventures portfolio company Umecrine Cognition invited to showcase Parkinson's disease program and new translational data at The Michael J.
Edit

Cerevance Announces Positive Phase 3 ARISE Results: Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease (Cerevance Inc)

Public Technologies 07 Oct 2026
Once-daily Oral Solengepras Meets Primary Endpoint and Demonstrates Motor and Non-motor Benefits in Parkinson's Disease ... The ARISE results support its potential to address both motor and non-motor symptoms of Parkinson's disease.
Edit

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

PR Newswire 06 Oct 2026
Parkinson's disease is characterized by the progressive degeneration of dopamine-producing neurons in the brain.2 While levodopa remains the cornerstone of symptomatic treatment, many people ...
Edit

Is Parkinson’s Disease a Man-Made Epidemic?

The Epoch Times 02 Oct 2026
Twelve million people worldwide are living with Parkinson’s disease ... Although records of possible Parkinson’s disease can be found in very early texts, ...
Edit

Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

PR Newswire 02 Oct 2026
Lundbeck A/S (Lundbeck) today announced that data from its movement disorders pipeline will be presented at the International Congress of Parkinson's disease and Movement Disorders® (MDS) 2026, taking place in Seoul, South Korea (4-8 October).
Edit

New Parkinson's drug gains approval in the US (Parkinson's Disease Society of the United Kingdom)

Public Technologies 30 Sep 2026
Parkinson's Disease Society of the United Kingdom published this content on September 29, 2026, and is solely responsible for the information contained herein.
Edit

Mike Tindall shares dad's 'horrible' final days after two-decade battle with Parkinson's disease

The Mirror 30 Sep 2026
Mike, who is married to the King's niece Zara Tindall, announced last week the death of his father Phil at the age of 80 following a two-decade battle with Parkinson's disease ... .
×